Antigenics' Oncophage Data Boosts Shares
by Jon C. Ogg
24/7 Wall St.
Antigenics (AGEN) saw its shares pop more than 20% as it released data in apress release regarding its Oncophage trials. The company's follow-up 'end of study' data on Phase III therapeutic cancer cvaccines showed that in a substantial subset of patients at intermediate risk for disease recurrence, Oncophage demonstrated a clinically significant improvement in recurrence-free survival of approximately 45 percent; and for intermediate-risk patients there was a trend towards improved overall survival, the study's secondary endpoint.
This data was presented at the American Urological Association and this may be the only such treatments approved for these patients. This data may be new observations, but the cut off date was back in January of 2006.
Continue article at 247WallSt.com
____________________
24/7 Wall St.
Antigenics (AGEN) saw its shares pop more than 20% as it released data in apress release regarding its Oncophage trials. The company's follow-up 'end of study' data on Phase III therapeutic cancer cvaccines showed that in a substantial subset of patients at intermediate risk for disease recurrence, Oncophage demonstrated a clinically significant improvement in recurrence-free survival of approximately 45 percent; and for intermediate-risk patients there was a trend towards improved overall survival, the study's secondary endpoint.This data was presented at the American Urological Association and this may be the only such treatments approved for these patients. This data may be new observations, but the cut off date was back in January of 2006.
Continue article at 247WallSt.com
____________________
posted by Nico at
7:07 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home